Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Wedbush analyst Martin Fan has reiterated an 'Outperform' rating on Zenas BioPharma (NASDAQ: ZBIO) and maintained a price target of $45 for the stock. No additional financial figures or strategic changes were mentioned in the article.